Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Cancer Vaccine AV-GBM-1 Improves PFS in Newly Diagnosed Glioblastoma

November 17th 2020

November 17, 2020 - AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival in patients with newly diagnosed glioblastoma.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

FDA Grants Nivatrotamab Orphan Drug Status for Pediatric Neuroblastoma

October 8th 2020

The FDA has granted an orphan drug designation and rare pediatric disease designation to the bispecific antibody nivatrotamab for the treatment of patients with neuroblastoma.

FDA Issues Refusal to File Letter for Omburtamab for Pediatric Metastatic Neuroblastoma

October 5th 2020

The FDA has issued a Refusal to File letter regarding the biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma.

Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

August 26th 2020

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

ERC1671 Immunotherapy Shows Early Promise in Recurrent Glioblastoma

August 26th 2020

The investigational immunotherapeutic ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab showed promising activity in patients with recurrent glioblastoma.

Dr. Reardon on a Phase 1/2 Trial Examining INO-5401 and INO-9012 in Glioblastoma

August 20th 2020

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

FDA Grants Fast Track Status to Paxalisib for Glioblastoma

August 20th 2020

The FDA has granted a fast track designation to paxalisib for the treatment of patients with glioblastoma.

Dr. Reardon on the Potential Utility of INO-5401 and INO-9012 in Glioblastoma

August 18th 2020

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

FDA Approval Sought for Omburtamab in Pediatric Metastatic Neuroblastoma

August 6th 2020

The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.

FDA Grants Fast Track Status to Enzastaurin for Newly Diagnosed Glioblastoma

July 22nd 2020

The FDA has granted a fast track designation for the PKCβ inhibitor enzastaurin for the treatment of patients with newly diagnosed glioblastoma.

Investigators Take Aim at GBM With a Biomarker-Driven Approach

July 21st 2020

Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma

Rolling BLA Submitted to FDA for Omburtamab in Pediatric Metastatic Neuroblastoma

June 30th 2020

A biologics license application has been submitted to the FDA for omburtamab, previously referred to as burtomab, for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

FDA Grants Berubicin Orphan Drug Status for Brain Cancer

June 11th 2020

The FDA has granted an orphan drug designation to berubicin for the treatment of patients with malignant gliomas.

FDA Grants Naxitamab Priority Review for Relapsed/Refractory High-Risk Neuroblastoma

June 3rd 2020

The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14th 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

AV-GBM-1 Active in Frontline Glioblastoma

April 8th 2020

AV-GBM-1 showed early promise in an interim overall survival analysis of an ongoing phase II trial in patients with newly diagnosed glioblastoma.

Paxalisib Shows Positive Survival Data in Glioblastoma

April 8th 2020

Treatment with paxalisib, an investigational small molecule inhibitor of the PI3K/AKT/mTOR pathway, was associated with a positive overall survival signal in patients with glioblastoma.

FDA Approval Sought for Naxitamab in Neuroblastoma

April 4th 2020

A Biologics License Application has been filed with the FDA for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

The Importance of Combination Immune Therapy in Orthotopic Murine Glioblastoma

January 30th 2020

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.